Subscribe to Newsletter

Cepheid

About Cepheid's Oncology Tests

Cepheid’s innovative oncology program offers a growing menu of molecular diagnostic tests that currently focuses on cancers of the breast, bladder, and blood. Leveraging Cepheid’s proven molecular diagnostics platform, our oncology products deliver on-site, on-demand, accurate, and reliable results. The pioneering mindset of our team is bolstered by Cepheid’s strong molecular biology capabilities, extensive global infrastructure, and an unwavering commitment to scientific rigor. Our vision is to deliver life-changing technology to physicians and their cancer patients globally.

Visit www.cepheid.com/en to view our entire portfolio of molecular diagnostic tests and systems.

1. CE-IVD. In Vitro Medical Device. Not available in all countries. Not available in the United States. 
2. Xpert® Breast Cancer STRAT4 Package Insert. Sunnyvale. USA. 2017

Contact Information:

Cepheid | Vira Solelh | 81470 Maurens-Scopont, France
PHONE +33.563.82.53.00
FAX +33.563.82.53.01

Company website

Content by Cepheid:

Product Profiles

Cepheid’s molecular test determines ER/PR/HER2/Ki-67 with less variable results compared to IHC/FISH

| Contributed by Cepheid

Xpert® Breast Cancer STRAT4 simplifies the molecular detection of ER/PR/HER2/Ki-67 in FFPE sections and provides results in less than 2 hours.

Webinars on Demand

Subspecialties Oncology

Two Perspectives: Patient and Hematopathologist Discussion on Importance of CML Monitoring

| Sponsored by Cepheid

Patients diagnosed with CML 20 years ago could live for around five years.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register